Headline: New CPT code 1000T defines autologous muscle progenitor cell injection into the urethral sphincter.

Lead: CPT code 1000T captures a targeted procedure in which a provider injects a patient’s own muscle progenitor cells into the urethral sphincter, with cystoscopy and ultrasound imaging performed as needed. The code represents a tissue-based therapeutic approach aimed at improving sphincter muscle function for patients with certain types of urinary incontinence.

What this code represents and why it matters: As a distinct procedural code, CPT code 1000T standardizes reporting for autologous muscle progenitor cell injections into the urethral sphincter, enabling clearer tracking of utilization, outcomes, and coverage decisions nationwide. The code matters for clinicians, billing teams, and payers because it delineates a specialized regenerative technique that may affect reimbursement pathways and prior authorization processes.

Key payers covered: Analysis typically addresses major national payers including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

What readers will learn: The publication provides benchmarks for utilization and reimbursement where available, summarizes clinical context for the procedure, outlines common coding and billing considerations tied to the service line, and notes relevant policy developments affecting coverage and prior authorization. Data not available in the input will be noted explicitly in specific sections.